Obsessive-compulsive and spectrum disorders: Overview and quality of life issues

Journal of Clinical Psychiatry

Volumn 57, Issue SUPPL. 8, 1996, Pages 3-6

  Hollander, Eric ^a   Kwon, Jee H ^a   Stein, Dan J ^a   Broatch, James ^a   Rowland, Clayton T ^a   Himelein, Carol A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

BEHAVIOR THERAPY; CLINICAL FEATURE; COMPULSION; HEALTH CARE COST; HUMAN; HYPNOSIS; OBSESSION; PRIORITY JOURNAL; PSYCHOANALYSIS; QUALITY OF LIFE; REVIEW;

ADOLESCENT; ADULT; AGE OF ONSET; BEHAVIOR THERAPY; COST OF ILLNESS; FAMILY PRACTICE; HEALTH CARE COSTS; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; QUALITY OF LIFE; SEROTONIN AGENTS; TREATMENT OUTCOME;

EID: 0029788047     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (5)

1. Karno M, Golding JM, Sorenson SB, et al. The epidemiology of obsessive-compulsive disorder in five U.S. communities. Arch Gen Psychiatry 1988;45:1094-1099
2. Robins LN, Heîzer JE, Weissman MM, et al. Lifetime prevalence of specific psychiatric disorder in three sites. Arch Gen Psychiatry 1984;41: 949-958
3. Hollander E. Introduction. In: Hollander E, ed. Obsessive-Compulsive Related Disorders. Washington, DC: American Psychiatric Press; 1993: 1-17
4. Hollander E, Stein D, Broatch J, et al. A pharmaco-economic and quality of life study of OCD. In: Scientific Abstracts of the 34th Annual Meeting of the American College of Neuropsychopharmacology; December 11-15, 1995; San Juan, Puerto Rico. Page 155
5. Dupont R, Rice D, Shiraki S, et al. Economic costs of obsessive-compulsive disorder. Pharmacoeconomics 1995;April:102-109